ArticleNew microbes and new infections2016
Distribution of innate efflux-mediated aminoglycoside resistance among different Achromobacter species.
Article in New microbes and new infections, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Genomic insights into efflux-mediated biofilm persistence and multidrug resistance in Achromobacter xylosoxidans from cystic fibrosis.Archives of microbiology · 2026Article
- Epidemiology ofNew microbes and new infections · 2026Article
- Comparative phenotypic and genotypic antimicrobial susceptibility surveillance inMicrobiology spectrum · 2025Article
- Genetic and Biochemical Characterization of AXC-2 fromPathogens (Basel, Switzerland) · 2024Article
- Role of Efflux in Antibiotic Resistance ofFrontiers in microbiology · 2022Article
- Role of RND Efflux Pumps in Drug Resistance of Cystic Fibrosis Pathogens.Antibiotics (Basel, Switzerland) · 2021Review
- Review
- Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-ResistantAntimicrobial agents and chemotherapy · 2020Article
- Review
- First Documented Case of Percutaneous Endoscopic Gastrostomy (PEG) Tube-Associated Bacterial Peritonitis due toCase reports in gastrointestinal medicine · 2020Article
- Fluoroquinolone-resistant Achromobacter xylosoxidans clinical isolates from Serbia: high prevalence of the aac-(6')-Ib-cr gene among resistant isolates.Folia microbiologica · 2019Article
- Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans.Scientific reports · 2018Article
- Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.Antimicrobial agents and chemotherapy · 2017Article
- A Pan-Genomic Approach to Understand the Basis of Host Adaptation in Achromobacter.Genome biology and evolution · 2017Article
- Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin.Frontiers in cellular and infection microbiology · 2017Article
- Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples.Epidemiology and infection · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achromobacter spp. are emerging respiratory pathogens in cystic fibrosis patients. Since 2013 the genus Achromobacter includes 15 species for which innate antibiotic resistance is unknown. Previously the AxyXY-OprZ efflux system has been described to confer aminoglycoside (AG) resistance in A. xylosoxidans. Nevertheless, some Achromobacter spp. strains are susceptible to AG. This study including 49 Achromobacter isolates reveals that AG resistance is correlated with different Achromobacter spp. It is noteworthy that the axyXY-oprZ operon is detected only in AG-resistant species, including the most frequently encountered in cystic fibrosis patients: A. xylosoxidans, A. ruhlandii, A. dolens and A. insuavis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.